Revista de psiquiatria y salud mental最新文献

{"title":"Obsessive–compulsive symptoms in anxiety and depressive disorders: Influence of recent and/or traumatic life events","authors":"Arantxa Orozco ,&nbsp;Narcís Cardoner ,&nbsp;Cristina F. Aragón ,&nbsp;Salvador Ruiz-Murugarren ,&nbsp;María Vicens ,&nbsp;Miguel Ángel Álvarez-Mon ,&nbsp;Guillermo Lahera","doi":"10.1016/j.rpsm.2020.12.002","DOIUrl":"10.1016/j.rpsm.2020.12.002","url":null,"abstract":"<div><h3>Introduction</h3><p>A high prevalence of obsessive–compulsive symptoms (OCSs) in anxiety-depressive disorders ranging from 30 to 67% has been described.</p></div><div><h3>Objective</h3><p>This study aims to assess the presence and persistence of OCSs in an outpatient sample of subjects with anxiety and depressive disorders, as well as its relationship with recent life events (RLEs) and/or traumatic experiences (TEs).</p></div><div><h3>Method</h3><p>We conducted a prospective, observational, analytical study of 200 subjects with DSM-5 diagnoses of anxiety and/or depression. Participants were included by consecutive sampling and were evaluated at baseline and after 6–12 months (mean 8.5 months) of follow-up. The severity of the symptoms was assessed through the Hamilton Anxiety Scale (HARS) and Hamilton Scale for the evaluation of depression (HRSD-17), and comorbidity was assessed through the International Neuropsychiatric Interview (MINI). The Revised Inventory of Obsessions and Compulsions (OCI-R), the Recent Vital Changes Questionnaire (CVSV), and the Diagnostic Scale for Post-Traumatic Stress (PDS) were also administered.</p></div><div><h3>Results</h3><p>54% of the sample presented OCSs, and 30.5% presented one or more TEs throughout life. At the baseline visit, the presence of OCSs was associated with the severity of depressive symptoms (<em>p</em> <!-->=<!--> <!-->0.028), the presence of TEs (<em>p</em> <!-->&lt;<!--> <!-->0.01), symptoms of post-traumatic stress disorder (<em>p</em> <!-->&lt;<!--> <!-->0.01) and the number of RLEs (<em>p</em> <!-->&lt;<!--> <!-->0.01). Response rate at follow-up was 38%, and persistence of OCSs was found in 60.5% of patients, independent of depressive or anxious symptoms, but was associated with the number of RLEs (<em>p</em> <!-->&lt;<!--> <!-->0.01).</p></div><div><h3>Conclusion</h3><p>The presence of OCSs in patients with anxiety and depressive disorders is frequent and persistent. Anxious-depressive patients with a history of TEs and RLEs had higher OCS levels. These findings highlight the importance of early detection and the use of therapeutic strategies focused on resilience to stress and trauma.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 218-226"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120301294/pdfft?md5=8d2551f4d35f931ee739ef08de16ca08&pid=1-s2.0-S1888989120301294-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38747424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression","authors":"Victor Augusto Rodovalho Fava ,&nbsp;Luciana Maria Sarin ,&nbsp;Ana Cecília Lucchese ,&nbsp;Lorena Del Sant ,&nbsp;Eduardo Magalhães ,&nbsp;Rodrigo Simonini Delfino ,&nbsp;Marco Aurélio Tuena ,&nbsp;Carolina Nakahira ,&nbsp;Andrea Parolin Jackowski ,&nbsp;Guilherme Abdo ,&nbsp;Juliana Surjan ,&nbsp;Matheus Steiglich ,&nbsp;Matheus Ghossain Barbosa ,&nbsp;José Alberto Del Porto ,&nbsp;Acioly Luiz Tavares Lacerda ,&nbsp;Hugo Cogo-Moreira","doi":"10.1016/j.rpsm.2020.10.003","DOIUrl":"10.1016/j.rpsm.2020.10.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0<!--> <!-->mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24<!--> <!-->h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.</p></div><div><h3>Results</h3><p>The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.</p></div><div><h3>Conclusions</h3><p>Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 212-217"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120301178/pdfft?md5=8b99e6d2b06dcf3a387f454ce0eb0ade&pid=1-s2.0-S1888989120301178-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38505659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Los pacientes psiquiátricos son más vulnerables ante la ley de la eutanasia española?","authors":"Adrián Alacreu-Crespo ,&nbsp;Lucas Giner ,&nbsp;Philippe Courtet","doi":"10.1016/j.rpsm.2021.01.003","DOIUrl":"10.1016/j.rpsm.2021.01.003","url":null,"abstract":"","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 231-233"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989121000203/pdfft?md5=55aafbb6bfaa1c703336e0bf0050eac0&pid=1-s2.0-S1888989121000203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38867223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensibilidad y especificidad de los criterios diagnósticos DSM-5 en el trastorno del espectro autista en una muestra de niños y adolescentes españoles","authors":"Ana Blázquez Hinojosa ,&nbsp;Luisa Lázaro Garcia ,&nbsp;Olga Puig Navarro ,&nbsp;Eva Varela Bondelle ,&nbsp;Rosa Calvo Escalona","doi":"10.1016/j.rpsm.2019.10.004","DOIUrl":"10.1016/j.rpsm.2019.10.004","url":null,"abstract":"<div><h3>Background</h3><p>Controversy exists regarding the DSM-5 criteria for autism spectrum disorders (ASD). Given the mixed results that have been reported, our main aim was to determine DSM-5 sensitivity and specificity in a child and adolescent Spanish sample. As secondary goals, we assessed the diagnostic stability of DSM-IV-TR in DSM-5, and clinical differences between children diagnosed with an ASD or a social (pragmatic) communication disorder (SPCD).</p></div><div><h3>Methods</h3><p>This study was carried out in 2017, reviewing the medical records of patients evaluated in our service. Items from a parent report measure of ASD symptoms (Autism Diagnostic Interview-Revised) were matched to DSM-5 criteria and used to assess the sensitivity and specificity of the DSM-5 criteria and current DSM-IV criteria when compared with clinical diagnoses.</p></div><div><h3>Results</h3><p>DSM-5 sensitivity ranged from 0.69 to 1.00, and was higher in females. By age, the DSM-5 and DSM-IV-TR criteria showed similar sensitivity. In the case of intellectual quotient, DSM-5 criteria sensitivity was lower for those in the “low-functioning” category. DSM-5 specificity ranged from 0.64 to 0.73, while DSM-5 specificity was similar for all phenotypic subgroups. With respect to stability, 83.3% of autism disorder cases retained a diagnosis of ASD using the DSM-5 criteria. With regard to differences between ASD and SPCD, we found that patients diagnosed with ASD received more pharmacological treatment than those diagnosed with SPCD.</p></div><div><h3>Conclusions</h3><p>Further research is required to confirm our results. Studies focusing on the SPCD phenotype will be necessary to determine outcome differences with ASD and the most effective diagnostic and therapeutic tools.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 202-211"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989119300990/pdfft?md5=79259de42c79d30e7bf5bb92caa7ab58&pid=1-s2.0-S1888989119300990-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37480791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intoxicación por litio: la amenaza SILENTiosa","authors":"Álvaro Martínez-Martín ,&nbsp;Álvaro Sánchez-Larsen ,&nbsp;Carolina Sánchez-Mora ,&nbsp;Rocío Sáez-Povedano ,&nbsp;Tomás Segura","doi":"10.1016/j.rpsm.2020.06.006","DOIUrl":"10.1016/j.rpsm.2020.06.006","url":null,"abstract":"","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 233-234"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120300756/pdfft?md5=7c639bb6920c68b54166d7a59b8be2a0&pid=1-s2.0-S1888989120300756-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38200848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real clinical setting intravenous ketamine use for treatment resistant depression: 12 month follow-up after initial response","authors":"Nora Olazabal ,&nbsp;Sonia Bustamante ,&nbsp;M. Aranzazu Madrazo ,&nbsp;Luis Osa ,&nbsp;Ana M. O’Neill of Tyrone ,&nbsp;Ana Catalán ,&nbsp;Miguel Angel González-Torres","doi":"10.1016/j.rpsm.2021.01.002","DOIUrl":"10.1016/j.rpsm.2021.01.002","url":null,"abstract":"","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 227-229"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989121000197/pdfft?md5=01bcfa21c34c9cfd58207dc439e6c942&pid=1-s2.0-S1888989121000197-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25311706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detección de ansiedad y depresión en Atención Primaria: utilidad de 2 escalas breves adaptadas a los nuevos criterios CIE-11-AP","authors":"Celso Iglesias García ,&nbsp;Pilar López García ,&nbsp;José Luis Ayuso Mateos ,&nbsp;José Ángel García ,&nbsp;Julio Bobes","doi":"10.1016/j.rpsm.2019.12.001","DOIUrl":"10.1016/j.rpsm.2019.12.001","url":null,"abstract":"<div><h3>Introduction</h3><p>The World Health Organization has developed a new classification of mental disorders in Primary Health Care (PHC), the ICD-11-PHC, in which there are changes in the diagnostic criteria of anxiety and depression disorder. In addition, 2 screening instruments have been developed for the detection of anxious and depressive symptoms according to the criteria of the new classification.</p></div><div><h3>Objectives</h3><p>To evaluate the capacity of the Spanish version of the 2 brief scales Dep5 and Anx5 to identify cases of depression and anxiety in PHC in Spain.</p></div><div><h3>Method</h3><p>A cross-sectional study conducted by 37 PHC physicians who selected 284 patients with suspected emotional distress. This sample was administered the screening scales (Anx5 and Dep5) and a diagnostic instrument (Clinical Interview Schedule-Revised) contemplating the new ICD-11 criteria as used as gold standard.</p></div><div><h3>Results</h3><p>The Anx5, using a cut-off point of 3, showed a sensitivity of 0.75 and specificity of 0.53. Using a cut-off point of 4, the Dep5 showed a sensitivity of 0.48 and a specificity of 0.8. The 2 scales together, with a cut-off point of 3 for each, classified correctly 73,57% as cases or non-cases. The diagnosis most frequently observed was anxious depression.</p></div><div><h3>Conclusions</h3><p>The screening scales for anxious and depressive symptoms (Anx5 and Dep5) are simple and easy-to-use instruments for assessing anxious and depressive symptoms in PHC. The reliability and validity data of each of the scales separately are limited but the figures improve when they are used together.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 196-201"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120300148/pdfft?md5=896ac08fa4679a9b4c3c2dee633d8bfc&pid=1-s2.0-S1888989120300148-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37601872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depression in late life: Linking the immunometabolic dysregulation with clinical features","authors":"Alejandro de la Torre-Luque ,&nbsp;Jose Luis Ayuso-Mateos","doi":"10.1016/j.rpsm.2021.06.004","DOIUrl":"10.1016/j.rpsm.2021.06.004","url":null,"abstract":"","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 4","pages":"Pages 181-185"},"PeriodicalIF":9.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989121000653/pdfft?md5=efb83bb047c0fdc1a5b6bc6f035134a5&pid=1-s2.0-S1888989121000653-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39155272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)","authors":"Mayoral-van Son J. ,&nbsp;Marcos Gómez-Revuelta ,&nbsp;Rosa Ayesa-Arriola ,&nbsp;Javier Vázquez-Bourgón ,&nbsp;Víctor Ortiz-García de la Foz ,&nbsp;Miguel Ruiz-Veguilla ,&nbsp;Nathalia Garrido ,&nbsp;Diana Tordesillas-Gutiérrez ,&nbsp;Esther Setién-Suero ,&nbsp;Benedicto Crespo-Facorro","doi":"10.1016/j.rpsm.2021.01.004","DOIUrl":"10.1016/j.rpsm.2021.01.004","url":null,"abstract":"<div><h3>Background</h3><p>Selecting the most effective treatment represents a critical challenge with the potential of modifying the long-term prognosis of individuals suffering a first break of psychosis. Head-to-head clinical trials comparing effectiveness among antipsychotic drugs in individuals with a first-episode of non-affective psychosis (FEP) are scarce.</p></div><div><h3>Methods</h3><p>The rationale and design of a 3 phases clinical trial (PAFIP-3, <span>NCT02305823</span><svg><path></path></svg>) comparing the effectiveness of aripiprazole and risperidone, and to additionally assess the benefits of an early use of clozapine in primary treatment-resistant patients is reported. The design encompasses of 5 work packages (medication algorithm, cognitive functioning, psychoeducation/vocational functioning, imaging and biological markers) addressing critical issues and needs of first episode psychosis individuals and their cares. The primary outcome measure was treatment effectiveness assessed by all-cause treatment discontinuation rate.</p></div><div><h3>Results</h3><p>266 individuals have been included in the randomization study phase I (risperidone vs. aripiprazole). At 3 months, the retention rate was of 94% (249/266), 48(19.3%) patients have gone through phase II (olanzapine treatment), and 7(2.8%) entered the clozapine phase (phase III).</p></div><div><h3>Discussion</h3><p>The PAFIP 3 clinical trial may provide relevant information about clinical guidelines to optimally treat patients with a first episode of non-affective psychosis and the benefits and risks of an early use of clozapine in treatment resistant patients.</p><p>Clinicaltrials.gov: <span>NCT02305823</span><svg><path></path></svg>.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 3","pages":"Pages 157-163"},"PeriodicalIF":9.2,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989121000215/pdfft?md5=4c865a3c729d7be9be5e792339b6a809&pid=1-s2.0-S1888989121000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85666110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amerindians may need clozapine dosing similar to that of Asians","authors":"Dinora F. González-Esquivel ,&nbsp;Helgi Jung-Cook ,&nbsp;Trino Baptista ,&nbsp;Jose de Leon","doi":"10.1016/j.rpsm.2020.11.002","DOIUrl":"10.1016/j.rpsm.2020.11.002","url":null,"abstract":"","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":"14 3","pages":"Pages 177-179"},"PeriodicalIF":9.2,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120301257/pdfft?md5=37d903869ff7fe4f21c5fda490797559&pid=1-s2.0-S1888989120301257-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80534485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}